Upregulation of NEK2 is associated with drug resistance in ovarian cancer
Upregulation of NEK2 is associated with drug resistance in ovarian cancer
复制标题
NEK2 的上调与卵巢癌的耐药性相关。
DOI：
10.3892/or.2013.2910
复制
发表时间：
2014-02-01
期刊：
影响因子：
4.2
通讯作者：
Yin, Fuqiang
中科院分区：
文献类型：
--
作者：
Liu, Xia;Gao, Yutao;Yin, Fuqiang
NEK2 [NIMA （never in mitosis gene A）相关表达激酶2]在癌症发生发展过程中与多种生物学行为相关，但其与耐药的关系研究有限。NEK2与卵巢癌耐药的关系尚未见报道。在本研究中，基于Oncomine和GEO Profiles在线数据库的微阵列结果，我们发现NEK2 mRNA在卵巢癌组织中的表达上调。此外，它在耐药卵巢癌细胞中的表达比在敏感或亲代卵巢癌细胞中的表达上调。最后，我们进行了全面的生物信息学分析，包括蛋白质/基因-蛋白质/基因相互作用网络，生物过程注释和microRNA-mRNA相互作用分析。我们观察到NEK2直接或间接地与许多与卵巢癌和其他类型癌症耐药相关的基因、蛋白质、microrna和生物过程相互作用。这些结果表明NEK2参与卵巢癌的耐药，可能是一个重要的治疗靶点。
NEK2 [NIMA (never in mitosis gene A)-related expressed kinase 2] is associated with various biological behaviors in the development of cancer, while research concerning its association with drug resistance is limited. The association of NEK2 with drug resistance in ovarian cancer has not yet been reported. In the present study, on the basis of microarray results from Oncomine and the GEO Profiles online database, we revealed that NEK2 mRNA expression in ovarian cancer tissues is upregulated. In addition, its expression in drug-resistant ovarian cancer cells was upregulated when compared with expression with their sensitive or parental counterparts. Finally, we performed a comprehensive bioinformatic analysis consisting of protein/gene-protein/gene interaction network, annotation of biological processes and microRNA-mRNA interaction analysis. We observed that NEK2 directly or indirectly interacts with a number of genes, proteins, microRNAs and biological processes associated with drug resistance in ovarian and other types of cancer. These results indicate that NEK2 contributes to drug resistance in ovarian cancer and it may be an important therapeutic target.